Piyachat Evelyn Roopngam1. 1. Clinical Immunology Laboratory, Faculty of Medical Technology, Western University, T. Sralongrua, A. HuayKra Chao, Kanchanaburi, Thailand.
Abstract
BACKGROUND: Infection with human papillomavirus type 16 (HPV-16) is known to cause cervical cancer, hence the several HPV therapeutic vaccines are developed in E7 oncoproteins and targeted on cell-mediated immunity. Human dendritic cells (HuDCs) are extensively employed in HPV therapeutic vaccines as the carrier or platform for inducing adaptive immune responses. However, the immunomodulators need to be further investigated for vaccine effects. Gray oyster mushroom (Pleurotus sajor-caju) containing β-glucans is a potent immunomodulator with potential to be used in vaccines. OBJECTIVE: To study the effect of Pleurotus sajor-caju-β-glucan Polysaccharides (PBG) on human T-lymphocytes by use of the HuDCs' antigen presentation platform for HPV16 vaccine. METHODS: The HPV16-E7 recombinant proteins were constructed in E. Coli. HuDCs pulsed with E7 peptide were cocultured with the T-lymphocytes treated with and without PBG. The number of T-lymphocytes(CD4; CD8) was detected by flowcytometry, and the viral response of T-lymphocytes was measured via IFN-γ release. RESULTS: The PBG treated group of T-lymphocytes cocultured with the HuDCs pulsed by the HPV16-E7 proteins showed significantly higher numbers of T-lymphocytes and IFN-γ release compared with T-lymphocytes without PBG in vitro. Moreover, a significant improvement in the level of specific IgG neutralizing antibodies to HPV was found in a murine model. Further observed was an increase in the expansion of helper and cytotoxic T-cells and IFN-γ releases in human system. CONCLUSION: PBG treatment of T-lymphocytes could be a useful option for prophylactic and therapeutic vaccines in cervical cancer.
BACKGROUND: Infection with human papillomavirus type 16 (HPV-16) is known to cause cervical cancer, hence the several HPV therapeutic vaccines are developed in E7 oncoproteins and targeted on cell-mediated immunity. Human dendritic cells (HuDCs) are extensively employed in HPV therapeutic vaccines as the carrier or platform for inducing adaptive immune responses. However, the immunomodulators need to be further investigated for vaccine effects. Gray oyster mushroom (Pleurotus sajor-caju) containing β-glucans is a potent immunomodulator with potential to be used in vaccines. OBJECTIVE: To study the effect of Pleurotus sajor-caju-β-glucan Polysaccharides (PBG) on human T-lymphocytes by use of the HuDCs' antigen presentation platform for HPV16 vaccine. METHODS: The HPV16-E7 recombinant proteins were constructed in E. Coli. HuDCs pulsed with E7 peptide were cocultured with the T-lymphocytes treated with and without PBG. The number of T-lymphocytes(CD4; CD8) was detected by flowcytometry, and the viral response of T-lymphocytes was measured via IFN-γ release. RESULTS: The PBG treated group of T-lymphocytes cocultured with the HuDCs pulsed by the HPV16-E7 proteins showed significantly higher numbers of T-lymphocytes and IFN-γ release compared with T-lymphocytes without PBG in vitro. Moreover, a significant improvement in the level of specific IgG neutralizing antibodies to HPV was found in a murine model. Further observed was an increase in the expansion of helper and cytotoxic T-cells and IFN-γ releases in human system. CONCLUSION:PBG treatment of T-lymphocytes could be a useful option for prophylactic and therapeutic vaccines in cervical cancer.
Authors: Judith A Smith; Anjali A Gaikwad; Lata Mathew; Barbara Rech; Jonathan P Faro; Joseph A Lucci; Yu Bai; Randall J Olsen; Teresa T Byrd Journal: Front Oncol Date: 2022-06-22 Impact factor: 5.738